Business
MGC Pharma strikes exclusive world-wide product distribution agreement – Stockhead
Three-year deal with Swiss PharmaCan is for world-wide distribution of its anti-inflammatory product ‘We are very happy with the successful cooperation between…
Link copied toclipboard
- Three-year deal with Swiss PharmaCan is for world-wide distribution of its anti-inflammatory product
- ‘We are very happy with the successful cooperation between MGC and Swiss PharmaCan’ – Swiss PharmaCan CEO
- MGC Pharma to dispatch 40,000 units per quarter of its product to Swiss PharmaCan
Biopharma company MGC Pharmaceuticals (ASX:MXC) has stuck a worldwide supply and distribution agreement for its anti-inflammatory medicinal cannabis product that can be used to treat COVID-19.
…
Continue Reading
-
Noosa News20 hours agoYoung voices shape Sunshine Coast’s future
-
Business19 hours ago2 Low Cost Active ASX ETFs to consider
-
General23 hours agoDonald Trump threatens China with additional 50 per cent tariff as trade war threatens to escalate
-
Noosa News17 hours agoStar Entertainment signs $300m lifeline deal with US gaming giant Bally’s